Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Lymphoma 3Solid Tumors 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Carcinoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × darinaparsin × Clear all
NCT00591422 2012-07-19

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Alaunos Therapeutics

Phase 1 Unknown
23 enrolled
Tumor-Agnostic

Neoplasms

NCT00592163 2012-07-19

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Alaunos Therapeutics

Phase 1 Unknown
20 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡